<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc</title>
    <meta name="description" content="PF-07248144 suppresses this abnormal gene activity and thereby supresses cancer growth.; 15, 2025 /PRNewswire/ -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc&#x27;s clinical drug candidate discovered from Oncology One; Pfizer&#x27;s KATSIS-1 trial, a Phase 3 clinical trial of PF-07248144 combined with fulvestrant, is now published on clinicaltrials.gov." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc</h1>
<div class="muted">2025-09-15 04:06:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>PF-07248144 suppresses this abnormal gene activity and thereby supresses cancer growth.</li><li>15, 2025 /PRNewswire/ -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc&#x27;s clinical drug candidate discovered from Oncology One</li><li>Pfizer&#x27;s KATSIS-1 trial, a Phase 3 clinical trial of PF-07248144 combined with fulvestrant, is now published on clinicaltrials.gov.</li><li>The KATSIS-1 trial will have a broad international footprint, seeking to enrol up to 400 subjects across many trial sites including Australian hospitals and specialty breast cancer units.</li><li>MELBOURNE, Australia, Sept.</li><li>In certain cancers, KAT6A/B gene activity is dysregulated promoting cancer cell growth.</li><li>Although early detection has dramatically improved the overall survival rate of breast cancer, it is estimated that 10,000 – 12,000 Australians are currently living with metastatic disease.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/jointly-discovered-kat6i-molecule-originating-040600251.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Jointly+discovered+KAT6i+molecule+originating+from+Australian+research+has+initiated+Phase+3+in+HR%2B+HER2-+Breast+Cancer+with+Pfizer+Inc%0A%E2%80%A2+PF-07248144+suppresses+this+abnormal+gene+activity+and+thereby+supresses+cancer+growth.%0A%E2%80%A2+15%2C+2025+%2FPRNewswire%2F+--+A%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fjointly-discovered-kat6i-molecule-originating-from-australian-research-has-initi%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>